PIK3CA and gastric cancer: The results of two phase I/II clinical trials of SMO inhibitors in combination with conventional cytotoxic therapy, or with a PI3K inhibitor, for the treatment of advanced stage GC (BKM120) are also awaited (NCT00982592 and NCT01576666) [92].